Abeona Therapeutics Inc. (ABEO) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 283.63M USD. 52-week range 4.00 to 7.65 USD. Data as of 2026-10-09.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing ...